# Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
Canonical URL: https://biopharmsignal.com/news/ANVS/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group-25bf6caf
Ticker: ANVS
Company: Annovis Bio
Source: Annovis Bio
Published: 2025-12-03 13:00 EST
## Summary

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company...

## Article Body
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California.

The presentation builds on momentum from the Company’s recent Phase 3 PD biomarker data , showing that patients with amyloid co-pathology experience more pronounced cognitive decline, which is counteracted and reversed by buntanetap. In the same patients, buntanetap also reduces tau biomarkers, which are known to increase with disease severity.

The presentation will also debut a cross-study comparison of the completed trials, providing the most comprehensive look yet at cognitive outcomes across all tested indications by Annovis and highlighting the population that benefits most – patients with amyloid pathology. In both Parkinson’s and Alzheimer’s, individuals with biomarker-confirmed presence of amyloid experience the greatest cognitive gain following buntanetap. These findings further validate the drug’s mechanism as a translational inhibitor of neurotoxic aggregating proteins and support the Company’s next strategic steps.

Presentation details :

Title : Amyloid co-pathology, cognitive decline, and improvement in buntanetap-treated Parkinson’s disease dementia patients

Presenter : Maria Maccecchini, Ph.D., President and CEO

Format : Poster guided tour

Time of presentation : December 5, 6:15 p.m. PST

The data presented at the meeting will be posted on the Company's website following the conference.

The PSG Annual Meeting brings together leading investigators, coordinators, trainees, advocates, and allied stakeholders to advance collaborative research and showcase the latest advances and best practices in PD.

About Annovis Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn , YouTube , and X .

Investor Alerts Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts .

Forward-Looking Statements This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information: Annovis Bio Inc. 101 Lindenwood Drive Suite 225 Malvern, PA 19355 www.annovisbio.com

Investor Contact: Alexander Morin, Ph.D. Director, Strategic Communications Annovis Bio ir@annovisbio.com ‍
## Recent Company News
- 2026-07-07 11:00 EST — [Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease](https://biopharmsignal.com/news/ANVS/annovis-reaches-full-enrollment-in-pivotal-phase-3-trial-of-buntanetap-for-early-35d9e2ee) — Source: Annovis Bio
- 2026-07-01 12:00 EST — [Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer](https://biopharmsignal.com/news/ANVS/annovis-appoints-cheng-fang-ph-d-as-chief-scientific-officer-56e8ee3d) — Source: Annovis Bio
- 2026-05-26 12:00 EST — [Annovis Bio Regains NYSE Listing Compliance](https://biopharmsignal.com/news/ANVS/annovis-bio-regains-nyse-listing-compliance-d6911038) — Source: Annovis Bio
- 2026-05-20 12:00 EST — [Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants](https://biopharmsignal.com/news/ANVS/annovis-announces-pricing-of-15-0-million-public-offering-of-common-stock-and-ac-b755aa8d) — Source: Annovis Bio
- 2026-05-19 20:06 EST — [Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants](https://biopharmsignal.com/news/ANVS/annovis-announces-launch-of-proposed-public-offering-of-common-stock-and-accompa-8ec0d147) — Source: Annovis Bio
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)